The steady stream of biotechs aiming to list on the Nasdaq has continued, with Attovia Therapeutics and Braveheart Bio the ...

Smith opened up about the treatment which she received a month ago and how her migraine symptoms had been reduced as a result ...

Sanofi (ENXTPA:SAN) stock is drawing attention after the US Food and Drug Administration approved Sarclisa Escena, a ...

The U.S. Food ⁠and ⁠Drug Administration said ⁠on Friday it has approved a ​wearable form of Sanofi's blood cancer drug, ...

Thanks to booming sales of blockbuster obesity and diabetes treatments, the amount that Americans spent on prescription drugs this year is on track to surpass $1 trillion, according to a report ...

Sutherland Shire families whose lives have been completely derailed by severe eczema are urgently calling on the federal ...

The life-changing medication was recommended for children aged six to 11 in March 2022. Kids are still waiting.

Immunology is AbbVie's primary core competency. While the pharmaceutical company has successfully transitioned patients from Humira to its newer blockbusters, Skyrizi and Rinvoq, the Apogee ...

Shares of AbbVie ABBV rose more than 6% on Monday after the company announced that it entered into a definitive agreement to acquire clinical-stage biotech Apogee Therapeutics APGE for $135.11 per ...

AbbVie stock rallied today on the $10.9 billion acquisition of Apogee Therapeutics. Here’s how you should play ABBV shares at current levels.

AbbVie said today it would buy biotech Apogee Therapeutics for $10.9 billion, in its largest buyout in more than five years to strengthen its next-gen immunology pipeline.